 |
|
Bexarotene Gel
A Food and Drug Administration–Approved Skin-Directed Therapy for Early-Stage Cutaneous T-Cell Lymphoma
Arch Dermatol. 2002;138:398-399.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
MYCOSIS FUNGOIDES (MF) is the most common primary cutaneous T-cell lymphoma
(CTCL).1 It is characterized by malignant T
cells that infiltrate the skin or extracutaneous sites. Early-stage MF (limited,
generalized patch, and plaque, T1 and T2, stages IA-IIA) is typically limited
to the skin. Subsequently, the management of early-stage MF frequently involves
skin-directed therapies, which include topical glucocorticoids, nitrogen mustard
(mechlorethamine hydrochloride), carmustine, UV-B radiation, psoralen–UV-A
radiation, and electron-beam radiation therapy. Aggressive therapy with combination
chemotherapy does not result in a more favorable outcome compared with conservative
management with sequential skin-directed therapies. In fact, patch and plaque
lesions have been noted to persist throughout the course of chemotherapy regimens
or to quickly relapse after initial clearing. Patients with early-stage CTCL
have excellent prognoses when they are treated for their skin disease. The
overall long-term life expectancy of patients with limited patch or plaque
disease has been shown to be similar . . . [Full Text of this Article]
RELATED ARTICLE
Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell Lymphoma
Debra Breneman, Madeleine Duvic, Timothy Kuzel, Richard Yocum, Joseph Truglia, and Victor J. Stevens
Arch Dermatol. 2002;138(3):325-332.
ABSTRACT
| FULL TEXT
|
